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35. Standat dization in the Laboratory Control of Oral Anticoagulants
E.A. Lonlrcsn and H.C. Hnurnn
I believe that the final goal of our Subcommittee must be to propose lines along
which it would be possible to achieve comparability of the results obtained by the
various assay proced.ures used in the different countries for the control of otal
anticoagulant treatment. Out motivation, I think, has been to define the so-called
therapeotic range of hypocoagulability, which is the range of hypocoagulability
resulting in effective thtombosis prophylaxis andanacceptable bleeding tendency'
Such a Jefinition is badly needed for the design and evaluation of clinical trials and
to improve the treatment of individual patients.
Our personal efforts in this field have been facilitated by the extensive materiaL
offered bv the Leiden Thrombosis Service, which now compfises more than
10,000 patients, alargeproportion of whom have been andarc still treated on long-
term schedule. fn such alargematerial the rate of thrombosis and bleeding compli-
cations, if carefully watched, can sefYe as a reliable parametef to detetmine the
therapeutic range.
Over the years, three different thromboplastins have been used by our Service;
in their terms the therapeutic tange is as shown in Tablel'
Tabh l. Tberapeutic range ar defned for diferent tbromboplastin preparalions b1 tbe Leiden Thrombosis
Thromboplastin
Therapeutic range
percefitage acc. to
Quick and Owren
Human brain (Owren) (1954-1958)
Rabbit lung (Roche) (1959-1962)
Thrombotest (Nyegaard) (1963-1969)
15-30
15-30
5-10
Vith all three of these thromboplastin prepatations, similar clinical tesults were
obtained as judged from the rate of complications. Therefore, the conclusion to be
drawn from our practical expefience is that diffetent procedures and thrombo-
plastins can be equally useful.
Haematology Section of the Department of Medicine, Leiden University Hospital, and the
Leiden Thrombosis Service, Leiden, The Nethedands.
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Fig. 1. Comelation diagtams as obtained by comparison of prothrombin time ratios found in
a series of individual patients with two identical samples of one batch (batch 1901, left) and two
samples of two different batches (batches 1901 and 1906, right) of human brain thromboplastin.
Botch1910
Fig.2. Cottelation diagram as obtained by comparison of prothrombin time ratios found in
33 patients with two different preparations of human brain thromboplas 'ns, one prepared accord-
ing to Owren (batch 1910), the other being Poller's Manchester Comparative Reagent. Normal
ranges are indicated bv a cross.
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This is not sufplising if we suppose that the three procedufes and thrombo-
plastins used measule and indicate the defect induced by coumarin congenefs
similarly, and hence in comparable terms. This should be ttue at least in stabilized
patients, independent of whether they arc tteated with short- of long-acting
coumafin congefiefs.
In the frrst part of my preserrtation I hope to substantiate this hypothesis once
againby evidence.
To begin with, we may consider the experimental error. The error in coagulation
times found by a skilled operator is about 5'/, in terms of coefficient of vadation af
that time. The error amounts to about 7 o/o when ratios are consideted which are
calculated by dividing the patient's time by the normal time. This is illusttated
by Figs. 7 and 2.
Fig. 1 shows on the left the results obtained in individual patients when two
"ppri.ntly 
different human brain thromboplastins ^fe compared' As can be
e"pe.t"d ior identical preparations (two identical samples of one batch prepared
in our labotatory were compared), the correlation line is rectilinear, the steepness
of the line is 45", and the deviations from the line are such as to be expected for
operators skilled in the performance of coagulation tests. Note that the magnitude
oi deviation is independent of the size of the ratio. This is consistent with the
expefience that the etror is a constant pefcentage of the values found. The data
pr.sent.d on the right in Fig. 1 show that a very similar picture is arrived at when
iesolts obtained with two different batches of human brain thromboplastin are
compared. A very similar picture is found also if the tesults obtained with human
brain thromboplastin prepared in two different laboratories with two slightly differ-
entmethods are comPared (Fig.2).
If we considet the results obtained with two different procedures and thrombo-
plastins, i.e., Quick's procedure with the use of human brain thromboplastin and
Thrombotest, the correlation is still good, though with mote scattering. This is
shown in Fig.3.
The greater scattef is consistent with an additional variation of about 8o/o
(coefficient of variation). This is due not to a Iarger. experimefltal ettor, but to the
ia.t th^tin Quicks's procedure more than just the vitamin K-dependent coagula-
tion factors are rate-limiting and in Owren's procedure- no hematocrit correction
has been applied; in addition, a different sensitivity of the two thromboplastins
for the coagulation defect induced by coumarin congeners contributes to the
greater variation.
From the data so far presented and our experience with many other commercial
preparations it follows that the coagulation defect expressed in coagulation times
or irtios is indeed indicated in comparable terms by different methods and thrombo-
plastins. No outliets were obsetved (Fig'4).
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Fig.3. Correlation diagtam as obtained by comparison of coagulation time ratios found in
47 patients (23 treated with acenocoumarin and 24 with phenprocoumon) with two different
assay procedures. Thrombotest according to Owren and thi prothrombin time assay procedures
according to Quick with the use of human brain thromboplastin were compared.
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Fig.4. Correlation diagram as obtained when conventional percentages of coagulation activity
found v'ith two different assay procedures are compared in patients treated with acenocoumarin
(dots) and phenprocoumon (circles).
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Futther, if we consider the correlation curves as obtained when conventional
percentages * found with all the different thromboplastins are compared, it becomes
quite cleat that the percentages defined for the different procedures have a widely
different biological iiignificance andarc hatdly er er comparable. Table 2 shows the
thetapeutic range aimed at by out Thtombosis Service in terms of these conven-
tional percentages belonging to different procedures and thromboplastins com-
monly used on the Continent.
Table2. Tberapeatic range adopted , ,U:r*t,f::r[]riombosit Seruice for different thrombopla$iw and
Manufacturet's
proposal
Geigy's thromboplastin
Human brain thromboplastin
Roche thromboplastin
Simplastin
Thrombotest
L5-25
15-30 (Poller)
15---25
11-25
10-20
20-34
r6-30
r6-30
18-35
5.+-70.5
Equivalents to 70-201o coagulation factor activity (mean activity of factors II and X) are
given in terms ofconventional percentages as defined by the different authors and manufactu(ers.
For patients without disease states providing contraindications and stabilized
on long-term treatmerit, the optimal range of the coagulation factors II, VII, IX,
and X has empirically proven to be 10-200/" of normal. The data given in
Table 2 show that the percentages defined by Quick are distinctly higher than
those found fot the coagulation factot. activity, whereas for Thrombotest the
opposite is the case. The main reason for the factthat percentages as defined by
Quick are all distinctly higher than those found for coagulation factors is that for
Quick's method the percentages are calculated by reference to coagulation times
obtained with normal plasma diluted in saline, which means that dilution of
factor V plays a role. Howevet, mutual differences between percentages according
to Quick as obtained with the various thromboplastins are also present. These, and
patticulafly the low percentages found rrith Thrombotest, arc the result of a sec-
ond biological action of coumarin congeners, known since 1963 (4), namely the
appeatance in the circulation of a more or less constant amount of metabolic
precursor of prothrombin, called PIVKA (Protein lnduced by Vrtamin K Ab-
sence or Antagonistt. PIVKA competitively inhibits thrombin formation; the
degree to which PIVKA is monitored by the diffetent thromboplastins varies
* Percentages defined by Quick (prothrombin time assay procedure) and Owren (Thrombo-
test).
Equivalent to levels of
t0 to 20o/o coagulation
factor activity
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widely: for instance, fabbit brain preparations have proven to have little sen-
sitivity to PIVKA, whereas ox btain and human brain prepalations are cleaiy
sensitive. These differences in sensitivitY appea;f to be of no principal impoftance,
given the good correlation between results obtained with insensitive (e.g., Sim-
plastin) and sensitive (e.g., Thrombotest) thromboplastins in patients on long-
term anticoagwlant treatment (Fig. 5)'
Fig.5. Cotrelation diagram as obtained when coagulation time ratios found with Thtombotest
".J.o-pur.d 
with tho-se found with Quick's one-stage assay procedure performed with the use
of SimPlast in.
The correlation does not differ from that shown in Fig. 3 for results obtained with
two PfVl(A-sensitive thromboplastins. This mearis that interindividual differences
in PIVI{A activity may not be as large as has been supposed'
On the basis of the data obtained in our comparative study on the various thtom-
boplastin prepafations and assay ptocedures in individual patients, we can only
conclude ih"ith.t" prepantions and procedures do not diffet principally in their
monitoring of the degree of individual coumatin-induced hlpocoagulability'
Differences between the preparations pettain mainly to the over-all sensitivity'
This conclusion is not new; in fact, it is only a confifmation of fesults reported by
Biggs as eafly as 1.964 (7,2). It is reassufing, howevet, with respect to the stand-
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ardizatton problem, because it means that any thromboplastin preparation can be
used as a reference. This brings us back to our major.oo."m, ihe problem of
standardization.
ft is clear that once we harre proven that allthromboplastin preparations give
us similar information in different terms - whether they be times, iatios, o, l"r-
centages must next look for a common denominator. The most sensible
definition of the defect induced by coumarin congeners would be to express it in
biochemical terms, as Eilers so rightly pointed out d.uring the Princeton meeting
in 1968 (3). our own approach has indeed been in this direction (5, 6). rMe have
attempted to define the coagulation defect in terms of shortage of the vitamin K-
dependent coagulation factors and the appearance in circulation of prVKA. The
shortage was chosen as ^  parameter for the magnitude of the defect, the level of
PrvKA being non-informative in this respecr, since it is independent of the
intensity of treatment.
1
1100o/ol
10(0o/ol5120%) 20l5%l
Fig.6. Schematic correlation lines found for the relationship between coagulation time ratios(indicated on the v-axis * *iilffi*?:l*'"T3fffliffi'ff: orthe prlthro-bi".";;i;;
The results we presented at Princeton were based on the study of pooled plasma(6). This year, we have extended our activities in three directions: first, the study
of seven different pooled plasmas, each containing equal amounts from 30 individual
patients treated at a cert^in level of stabilized anticoagulation; second, the investi-
gation of 15 individual patient plasmas; and third, the investigation of plasmas
obtained from one individual taken on eight different occasions during long-term
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Figs.7 and 8. Correlation diagrams showing the telationship referred to in Fig.6 as obtained
for different assay procedures andthromboplastins. The solid lines show the correlation as esti-
mated by eye for results of tests of abnormal plasma; the dotted line was obtained from normal
plasma (batch 1502) and its dilutions withAl (OH)r-adsorbed normal plasma. Solid dots represent
the results obtained with the seven pooled plasmas, open squares refer to the 15 randomly chosen
patients, and crossed squares to one volunteer checked on eight different expetimental anti-
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coagulations at different levels of intensity. Note that only results obtained with Thrombotest
are consisteflt with the hypothesis of a rectilinear correlatitn. Deviations from rectiline aity arcpaftict]Jar1y obvious for human brain, Roche, and Geigy thromboplastin. However, in the thera-peuti*anse (between t 
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treatment. The results of this urork are to be found in Figs.7 and B. Before looking
,t th.r. figures, it will be useful to recapitulate schematically what is known about
the relationship between the level of the factors of the prothrombin complex and
the coagulation times or fatios of patient's time to notmal time as found with a
girr.r, tilro-boplastin preparation ia.king the coagulation factors under investi-
gation (Fig.6)'
' 
t' nig. e] the relation in the absence of PfVKA is represented by the dotted line,
the relation in the presence of PrVKA (which is the patient's situation) by the bold
line. These relationships are tlpical fot enzyme reactions in the absence (dotted
tirr.; 
"rra 
presence (boid line) o? a constant amount of competitive inhibitor.
The most impoftant conclusion to be drawn ftom our data is that each thrombo-
plastin pr"prr"io' can be defined in terms of the biochemical defect induced by
coumarin congenefs' This is fat fuom afl easy job' however' -One needs catefully
prepared poo[d normal as well as patient's plasmas,_the stability of which has not
|.,L.., iully established. Far easier, and quite sufficient fot ptactical purposes,
is the definition in terms of a standard teference thromboplastin preparation 
as
proposed by Biggs and Denson, because theit approach tequires only one or two
iteshly prePared normal Plasmas'- 
N"i y.t dir.osr.d, but equally important for standardizationof the prothrombin
time assay procedures is the question of quality control in daily practice, where we
have to i..kor with rather large differences between batches, or, everr worse'
deterioration of thromboplastin prepatations'
In out |aboratoty this problem h", b".n solved by the use of pooled plasma,
normal as well u, abrror*al, which is stored at -70'c. The stability of these 
pooled
;hrr""r appears satisfactory for daily practice; their 
evaluation is now going on
in our laboratory to d.t..#ne theii suitability for the biochemical definition 
of
national ot international thtomboplastin preparations' .
Standards introduced by manufactorers oflhromboplastin pfeparations are also
".ry-"r"i"f 
in daily pru.ii".. For instance, the Thrombotest standard reference
culveaccompanyngeachbatchofThrombotestprovedtobeingoodagreement
with out noimal laboratoty standard (Table 3)'
As a conseiluence of another extremely important approach introduced by
Miale and LaFond rn7g62 (7), namely the use of plasma standards for monitoring
normal and abnormal levels n a*ty quality contiol, the manufacturers of Simpla-
stin have introduced three lyophiiir.d tt"ttd"rd plasmas, Diagnostic plasma, 
to
.h..k norm"lity, and Verify i and II, to check therapeutic levels' Although these
;;;;;;, rrurr" b."r, o.iy helpful for _users of 
simplastin, they appear to be
unsuitable as standardi z.d, qoahty conttol preparations for othet thromboplastin
prepantions because of laige differenc.s i" irt activity of factors vII and X,
contained in these preparations (Table 4)'
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Thrombotest
(batch no.) 100%
Leiden
10%
99
115
115
99
96
98
101
100
102.9
796
860
915
916
917
918
919
937
mean
, 
Values as defined by the manufacturer (left) and those found with deep-frozen normal pooled
plasma used by the Leiden Thrombosis Service (right) are compared.
Tab/e4. Ruul*found with Varner Cbilcott't Diagno$it plarma and Verifl I and II.
Read from specific assays
Diagnostic
Plasma Verify I Verify II
II
v
VII
X
- .  -  - - .  
" . , . . . . . T -  - , . . , . . ; ,  -  - ,  -  - . . . . . . . .  -  -  -
Read from prolongation ratios
(Figs. 1a and 1 b)
G
H B .
R
S
TT
95
105
150
120
22
90
55
10
10.5
75
10.5
J.. f
8.5
6.5
6.5
10.5
80
775
115
720
200
9
35
23
23
57;5
,The activity of the factors of the prothrombia complex was assessed individually by means
of specific one-stage assay procedures (upper columns) and collectively (lower columns) obtained
by transformation of the prolongation ratios found with different thromboplastin preparations(see Figs.7 and 8).
Particulatly in the two Verifys the level of facuorVll is much higher than that
of factor X. This probably explains the relatively high percentages found with
Thrombotest and human brain thromboplastin, both of which are known to be
factor VIr sensitive, lrhereas values found with Geigy thromboplastin, which is
factor VII insensitive, closely parallel the factor X activity.
4I
44
44
47
39
44
42
42
42.1
Tabh 3. Normal ualues found witb a nri6 of seuen dffirent batcbes of Tbrombotest,
40 100
44 712
43 110
43 105
39 98
43 101
42 I04
43 106
42.7 704.5
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SummarY
1. Quick's one-stage assay procedute with the use of human brain ot
long tiromboplastin and Owren's Thrombotest assay procedute with the use
o" f,min thtomboplastin have proved equally useful in practice
2. Thromboplastin standardtzatton according to Biggs andDenson has
proven to be satisfactory for all practical pu{poses; different PIVIS sensi
or,n. diffetent thromboplastins has no pdmary importance in this fespect.
3. The various assay procedures and thromboplastin preparations do not
pdncipally in their monitoring of the degree of the individual coumarin-ind
hypocoagulability.
"i. for ,fr. definition of the coumarill action in biochemical terms, and, eq
impoftant, for daily quality control, plasma standards are needed and hence
be develoPed.
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